Clinical trial NCT02831530: Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients
Official title: Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2016-07-13
Enrollment: 101
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cyclins CDK4 / 6 are extensively involved in the proliferation and growth of numerous cancers including breast cancer. The objective of this study is to identify if a new preoperative oral treatment, abemaciclib directed against the CDK / 6 compared to no treatment, inhibits tumor growth or induced senescence (aging) tumor.

This early study is offered to women who are going to be operated on for breast cancer with expression of hormone receptor (ER and / or PR). These women will have 3 chances to receive one for up to 14 days in the waiting period of their surgery abemaciclib as tablets. Other patients do not receive treatment. The decision to receive or no treatment will be done by a random computer draw.

The drug's effectiveness will be evaluated primarily on the biological parameters of the tumor itself when comparing surgery to before treatment. These results biomarkers will allow us to better know how this treatment and eventually will be used in future to identify patients for whom treatment with abemaciclib more efficiency.

Patients treated in the protocol will then receive treatment entirely conventional in their breast cancer within the parameters of their tumors: their participation is very limited in time.


Eligibility criteria: Inclusion Criteria:

1. Signed written informed consent
2. Female patients aged 18 years or older.
3. Histologically or cytologically confirmed untreated invasive carcinoma of the breast
4. Candidates for initial breast surgery with a minimum tumor size of 11 mm measured by breast ultrasound. Bilateral and multifocal tumors are allowed, assuming tumor evaluations and pre- and post-treatment biopsies are performed in the same target lesion.
5. HR-positive (defined as either ER and or PR expression \>10% by immunohistochemistry or by PCR) irrespective of HER2 status.
6. No evidence of metastatic disease.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0/1.
8. Left ventricular ejection fraction (LVEF) of at least 50%
9. Negative pregnancy test in women of childbearing potential within 14 days prior to treatment initiation (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization).
10. For women of childbearing potential who are sexually active, agreement to use a highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception during and for at least 6 months post-treatment.
11. Patients must be affiliated to a social security system

Exclusion Criteria:

1. Patients non-candidate for upfront breast surgery or candidate for neoadjuvant chemotherapy or hormonotherapy.
2. Patients receiving another concomitant anticancer treatment like chemotherapy, immunotherapy, endocrine treatment, or radiotherapy for the currently diagnosed tumor.
3. Known hypersensibility to abemaciclib or any of its components.
4. Difficulty to swallow oral medication.
5. Serious uncontrolled concomitant disease that would put the patient at high risk for treatment-related complications.
6. Patients whose general clinical condition does not consider postponing surgery.
7. Inadequate organ function, evidenced by the following laboratory results:

   * Absolute neutrophil count \<1,500 cells/mm3
   * Platelet count \<100,000 cells/mm3
   * Hemoglobin \<8 g/dL
   * Total bilirubin greater than 1,5 times the upper limit of normal (ULN) (unless the patient has documented Gilbert's syndrome)
   * Aspartate aminotransferase (AST \[SGOT\]) or alanine aminotransferase (ALT \[SGPT\]) \>3 x ULN
   * Serum creatinine \>2 mg/dL and/or clearance creatinine \<50mL/min (calculated by Cockcroft-Gault method)
8. Patients with serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis).
9. Patients with a personal history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
10. Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
11. Pregnant or breastfeeding patients

Primary outcomes:
measure: Anti-proliferative response
timeFrame: Assessed 15 days after randomization
Secondary outcomes:
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Gustave Roussy
state: Val De Marne
Study officials:
References: